1. Scrip
  2. >>Drug Pricing

CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged

 
• By Cathy Kelly

National formulary exclusions continue in 2017, with CVS aggressively expanding its list of “not covered” drugs. Express Scripts currently excludes slightly fewer drugs than last year but may still add to its list.

PS1607_FormularyCommitteePad_1200x675

CVS Health Corp. will exclude a total of 131 drugs from coverage under its standard national formulary in 2017 while Express Scripts Holding Co.’s national preferred formulary will exclude 85 drugs, according to recent announcements by the pharmacy benefit managers.

CVS and Express Scripts formularies each cover approximately 25 million individuals commercially insured through employers and health plans. The formulary exclusion lists for 2017 are available here and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 
• By Mary Jo Laffler

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 
• By Alaric DeArment

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.